Background: Plasmablastic Lymphoma (PBL), a rare and aggressive subtype of non-Hodgkin's lymphoma, often arises in immunosuppressed patients, including those with HIV or undergoing immunosuppressive treatments. Due to its rarity, a standardized approach to its management has been elusive. Our study evaluated the effectiveness of intensive chemotherapy and radiotherapy on survival outcomes in patients with PBL.

Methods: We conducted a comprehensive analysis using a pooled database, encompassing demographic data, molecular characteristics, and treatment responses of a retrospective cohort with confirmed PBL cases. Kaplan-Meier survival curves were constructed. Cox proportional hazards model and Log-rank tests were used to assess the survival impacts of various treatments.

Results: The study cohort comprised 300 confirmed PBL cases with a median age of 49. It predominantly consisted of males (M:F ratio of 2.7). Approximately 51% were diagnosed at advanced stages (III/IV), and 62% had an immunocompromised status, 47% due to HIV. Analysis showed a median overall survival (OS) and disease-free survival (DFS) of 25 and 15 months, respectively. Significant factors influencing OS included bone marrow, liver, lung/pleura, and upper GI tract involvements; all were associated with poorer outcomes. Conversely, early-stage <2 disease (p<0.0001), head and neck involvement (p=0.0001), and attaining CR (p<0.0001) were linked to better survival. Compared to no treatment, chemotherapy (CT) and stem cell transplant had incrementally better OS (2 vs. 27 vs. NR months, p<0.0001). Patients who underwent frontline intensive chemotherapy (ICT) had a superior OS compared to those treated with CHOP-like or myeloma protocols in decreasing order (p<0.0001). ICI survival benefit persisted when analyzed by early vs. advanced stages (p=0.0009). Radiotherapy (RT) improved OS when added to intensive and non-intensive CT (p=0.03). However, upon further analysis, RT benefits were restricted to those with early stages (I&II) H&N PBL (NR vs. 27mo; p=0.0008).

Conclusion: Our findings support an aggressive chemotherapy approach in managing Plasmablastic Lymphoma with the addition of radiotherapy in H&N early-stage disease. This approach maximizes survival and highlights the importance of tailored treatment strategies based on disease stage and location.

Disclosures

No relevant conflicts of interest to declare.

This content is only available as a PDF.
2024
Sign in via your Institution